{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpModified.=2019-10-02T19%3A15%3A14.098Z&tablingMemberConstituency=Birmingham%2C+Selly+Oak&title=House+of+Commons+Tabled+Parliamentary+Question+2017%2F19+291225&min-ddpModified.=2019-07-17T18%3A53%3A32.348Z&hansardHeading=Selective+Serotonin+Reuptake+Inhibitors%3A+Sexual+Dysfunction", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?max-ddpModified.=2019-10-02T19%3A15%3A14.098Z&tablingMemberConstituency=Birmingham%2C+Selly+Oak&title=House+of+Commons+Tabled+Parliamentary+Question+2017%2F19+291225&min-ddpModified.=2019-07-17T18%3A53%3A32.348Z&hansardHeading=Selective+Serotonin+Reuptake+Inhibitors%3A+Sexual+Dysfunction", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpModified.=2019-10-02T19%3A15%3A14.098Z&tablingMemberConstituency=Birmingham%2C+Selly+Oak&title=House+of+Commons+Tabled+Parliamentary+Question+2017%2F19+291225&_metadata=all&min-ddpModified.=2019-07-17T18%3A53%3A32.348Z&hansardHeading=Selective+Serotonin+Reuptake+Inhibitors%3A+Sexual+Dysfunction", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&max-ddpModified.=2019-10-02T19%3A15%3A14.098Z&tablingMemberConstituency=Birmingham%2C+Selly+Oak&title=House+of+Commons+Tabled+Parliamentary+Question+2017%2F19+291225&min-ddpModified.=2019-07-17T18%3A53%3A32.348Z&hansardHeading=Selective+Serotonin+Reuptake+Inhibitors%3A+Sexual+Dysfunction", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpModified.=2019-10-02T19%3A15%3A14.098Z&tablingMemberConstituency=Birmingham%2C+Selly+Oak&title=House+of+Commons+Tabled+Parliamentary+Question+2017%2F19+291225&min-ddpModified.=2019-07-17T18%3A53%3A32.348Z&hansardHeading=Selective+Serotonin+Reuptake+Inhibitors%3A+Sexual+Dysfunction", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpModified.=2019-10-02T19%3A15%3A14.098Z&tablingMemberConstituency=Birmingham%2C+Selly+Oak&title=House+of+Commons+Tabled+Parliamentary+Question+2017%2F19+291225&min-ddpModified.=2019-07-17T18%3A53%3A32.348Z&hansardHeading=Selective+Serotonin+Reuptake+Inhibitors%3A+Sexual+Dysfunction", "items" : [{"_about" : "http://data.parliament.uk/resources/1146686", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1146686/answer", "answerText" : {"_value" : "

The European Medicines Agency (EMA) has not formally recognised Post SSRI Sexual Dysfunction (PSSD) as a medical condition, as it is not within the remit of the EMA to classify medical conditions.<\/p>

The EMA\u2019s Pharmacovigilance Risk Assessment Committee evaluated the available safety data on the risk of sexual disorders with selective serotonin reuptake inhibitors/serotonin norepinephrine reuptake inhibitors to establish whether the existing information about the possible side effect of sexual dysfunction fully reflected the available evidence. The review did not include an evaluation of whether PSSD is a specific medical condition.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1481", "label" : {"_value" : "Biography information for Ms Nadine Dorries"} } , "answeringMemberConstituency" : {"_value" : "Mid Bedfordshire"} , "answeringMemberPrinted" : {"_value" : "Ms Nadine Dorries"} , "dateOfAnswer" : {"_value" : "2019-10-01", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-10-01T15:34:19.173Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-09-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Selective Serotonin Reuptake Inhibitors: Sexual Dysfunction"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department has taken, in light of the European Medicines Agency formally declaring that it recognises Post SSRI Sexual Dysfunction (PSSD) as a medical condition that can outlast discontinuation of SSRI and SNRI antidepressants, to provide symptomatic relief to those suffering from that condition on a long-term basis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/298", "label" : {"_value" : "Biography information for Steve McCabe"} } , "tablingMemberConstituency" : {"_value" : "Birmingham, Selly Oak"} , "tablingMemberPrinted" : [{"_value" : "Steve McCabe"} ], "uin" : "291225"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }